Cellero will be officially joining Charles River

We have some big news to share, and we’re glad you’re here to read about it! Today, Cellero has announced that we will officially be joining Charles River.  This exciting change will complement Charles River’s recent acquisition of HemaCare and allow our company to better serve a growing list of customers and partners across the…

Read more

Cellero Launches New Products to Support the Fight Against COVID-19

Convalescent COVID-19 T-cells, PBMC and Plasma Now Available LOWELL, MA – July 28, 2020 – Cellero, the leading provider of donor and patient collection services, GMP-grade biomaterials, characterized immune cells, and custom research services, today announced the launch of new convalescent COVID-19 blood products to support research and vaccine development. Blood products collected from convalescent…

Read more

Key Biologics and Astarte Biologics Rebrand as Cellero and Announce Completion of Phase One of $50 Million Multi-Year Expansion Plan

New brand and expansion reflect the company’s mission to support the development and delivery of tomorrow’s treatments and cures. MEMPHIS, TN and BOTHELL, WA – May 12, 2020 – Key Biologics and Astarte Biologics, together the leading provider of research- and clinical-grade human immune cells, blood products, and related services to the biopharmaceutical industry, today…

Read more

Key Biologics Joins the Fight Against COVID-19

Launches new program to supply blood products from COVID-19 convalescent donors LOWELL, MA and MEMPHIS, TN – April 29, 2020 – Key Biologics and Astarte Biologics, together the leading provider of research- and clinical-grade human immune cells, blood products, and related services to the biopharmaceutical industry, today announced the launch of an IRB-approved initiative to…

Read more
Astarte and Key Biologics logos

Key Biologics and Astarte Biologics Merge

Includes growth equity investment from Ampersand Capital Partners MEMPHIS, TN and BOTHELL, WA – August 7, 2018 – Key Biologics has completed its merger with Astarte Biologics to create the leading provider of research- and clinical-grade human immune cells, blood products, and related services to the biopharmaceutical industry. In conjunction with the merger, the new entity also received…

Read more
fresh and frozen whole leukaphereses

Key Biologics Accelerates CAR-T Research with New Leukaphereses Offerings

Also announces installation of Asymptote VIA Quad Freeze controlled-rate freezer MEMPHIS, TN, and MONTREAL QC, May 14, 2018 – Key Biologics LLC , a provider of biological raw materials and services for manufacturing cell-based therapeutics, today announced the availability of fresh and frozen whole leukaphereses from patients with hematologic malignancies; Multiple Myeloma, Non-Hodgkin Lymphoma, Chronic…

Read more